LeMaitre Vascular, Inc. (NASDAQ:LMAT) Insider Trent G. Kamke Sells 2,009 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $81.91 on Friday. The stock has a 50-day moving average price of $95.21 and a 200 day moving average price of $94.59. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58. The company has a market capitalization of $1.85 billion, a P/E ratio of 44.76, a P/E/G ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a $0.20 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital upped their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Finally, Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $95.25.

Institutional Trading of LeMaitre Vascular

Several large investors have recently added to or reduced their stakes in LMAT. Copeland Capital Management LLC increased its position in shares of LeMaitre Vascular by 0.7% during the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock valued at $107,990,000 after purchasing an additional 8,623 shares during the period. State Street Corp boosted its stake in shares of LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after acquiring an additional 28,525 shares in the last quarter. Congress Asset Management Co. boosted its stake in shares of LeMaitre Vascular by 1.8% during the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock worth $66,555,000 after acquiring an additional 13,009 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock worth $50,711,000 after acquiring an additional 7,737 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of LeMaitre Vascular by 5.1% during the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier’s stock worth $30,205,000 after acquiring an additional 15,843 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.